Quanterix (QTRX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Quanterix

NasdaqGM•Healthcare•Medical Devices

$2.73+0.04(0.01%)Pre-market

Market Cap

$147.16M

P/S

1.0x

P/B

0.6x

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

How this company scores

AverageMetricSide Score: 40/100

Strongest: Growth (15/25); weakest: Profitability (4/25).

Profitability4/25

Growth15/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Growing revenueInterest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1.0x5y range 1.0x – 16.5x

Currently below its 20-quarter median.

P/B · 0.6x5y range 0.6x – 3.9x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $147.16M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $153.41M
Q. Revenue: $32.91M
TTM EBITDA: $-129.47M
TTM Op. Income: $-152.87M
Q. Op. Income: $-49.43M
TTM Net Income: $-123.11M
Q. Net Income: $-48.93M
EPS: $-1.04
Shares Out.: $47.17M

$153.41M in TTM revenue grew 22.0% YoY, reaching $32.91M last quarter. TTM EBITDA of $-129.47M and TTM operating income of $-152.87M show growth is flowing through to the bottom line. However, net income is negative at $123.11M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 38.5%
EBITDA Margin: -131.6%
Op. Margin: -150.2%
Net Margin: -148.7%

Op. margin of -150.2% is up 1.4% YoY — cost efficiency is improving. Net margin at -148.7% and gross margin of 38.5% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.0x
P/B Ratio: 0.6x

P/S of 1.0x and P/B of 0.6x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $319.63M
Cash: $44.17M
Long-Term Debt: N/A
Book Value: $237.21M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-5.12M
TTM Free Cash Flow: $-81.68M
FCF Margin: -53.2%
FCF / Net Income: 0.7

TTM FCF of $-81.68M on $-5.12M in operating cash flow. The FCF / Net Income ratio of 0.7x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 148% — an improving trend.